Neuroscience 2000 Abstract
| Presentation Number: | 481.14 |
|---|---|
| Abstract Title: | MRI measures of brain atrophy in multiple sclerosis: associations with glucocorticoid treatment. |
| Authors: |
Reymond-Marron, I.*1
; Pruessner, M.1,2
; Pruessner, J. C.1,2
; Zijdenbos, A. P.2
; Charil, A.2
; Evans, A. C.2
1Douglas Hospital Research Centre, Verdun, Canada 2McConnell Brain Imaging Centre, Montréal Neurological Institute, Montréal, Canada |
| Primary Theme and Topics |
J. Disorders of the Nervous System and Aging - 132. Degenerative disease: other |
| Session: |
481. Degenerative disease: inflammation and multiple sclerosis Poster |
| Presentation Time: | Tuesday, November 7, 2000 9:00 AM-10:00 AM |
| Location: | Hall G-J |
| Keywords: | MS, HIPPOCAMPUS, VENTRICLE |
Brain atrophy is a consistent finding in patients with multiple sclerosis (MS). The present study investigated if the amount of glucocorticoids (GC), administered as treatment for acute episodes of MS, can serve as an additional explanatory factor for this finding. From a total of 379 patients with relapsing-remitting MS, baseline and two year follow up Magnetic Resonance Imaging (MRI) scans of 27 cases were selected. During the trial period, 14 patients had received high doses of glucocorticoid treatment, while 13 patients were without treatment. Subjects in both groups were matched for gender, age, and evaluation on the Expanded Disability Status Scale (EDSS) at study begin (0-4,5). T1 weighted images with 3mm axial contiguous slices were acquired. All MR images were transformed into standard stereotaxic space. Volumetric analyses were performed for white matter, gray matter, hippocampus, and ventricles using both manual and automatic segmentation procedures. The GC treatment group showed significant atrophy in all examined brain structures compared to the group without treatment. For all other variables, including the EDSS at study begin and end, no such differences were observed. Also, correlational results were more pronounced for GC than EDSS measures. These findings suggest a potential role of glucocorticoid treatment in brain atrophy in MS. Future studies need to further explore this association in other patient groups with high glucocorticoid treatment. The MRI scans were part of a multi-center, double-blind phase III clinical trial of Myloral (Autoimmune, Inc).
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2000 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2000. Online.
Copyright © 2000-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
